References
  1. Shirkey H. Editorial comment: Therapeutic orphans. The Journal of Pediatrics, 1968: 72(1): 119-120.
  2. Institute of Medicine. Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington DC: The National Academies Press. https://doi.org/10.17226/13311; 2012.
  3. PREA. Pediatric Research Equity Act (PREA). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK3997/
  4. BPCA. Best Pharmaceuticals for Children’s Act (BPCA). Retrieved from https://bpca.nichd.nih.gov/Pages/default.aspx
  5. Yondelis. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207953s005lbl.pdf
  6. Abraxane. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021660s046lbl.pdf
  7. Jevtana. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201023s023lbl.pdf
  8. Velcade. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf
  9. Afinitor. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf
  10. Treanda. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022249s024lbl.pdf
  11. Tasigna. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf
  12. Taxotere. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020449s083lbl.pdf
  13. Sutent. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021938s036lbl.pdf
  14. Methotrexate. USP. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011719s125lbl.pdf
  15. Xeloda. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020896Orig1s042lbl.pdf
  16. Eloxatin. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021759s023lbl.pdf
  17. Zometa. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf
  18. phosphate. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022137s003lbl.pdf
  19. Arimidex. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf
  20. Camptosar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
  21. Temodar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022277s013lbl.pdf
  22. Navelbine. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020388s037lbl.pdf
  23. Gemzar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf
  24. Honig, S. 2002. Medical review for Navelbine (vinorelbine). NDA 20388/S014. Nov. 2002. Silver Spring, MD: Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020388_S014_NAVELBINE_INJECTION _AP.pdf (accessed April 3, 2012)
  25. Gemzar (gemcitabine HCL) pediatric written request. Jan. 2001. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/88726/download
  26. Pediatric Exclusivity Granted, Apr. 2016. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/79154/download
  27. Shapiro, A. 2003. Medical review for Temodar (Teozolomide). NDA 21029/S005. Mar. 2003. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/92216/download
  28. Ibrahim, A. 2003. Medical review for Camptosar (Irinotecan). NDA 20571/S021. Dec. 2003. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/files/drugs/published/N20-571S023-Irinotecan-Clinical-BPCA.pdf
  29. Vaidyanathan, J. 2008. Clinical pharmacology review for Anastrozole (Arimidex). NDA22214. Feb. 2008. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/75522/download
  30. Cohen, M. 2003. Medical review for Fludarabine Phosphate. NDA 20038. July 2003. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/files/drugs/published/N20-038S028-Fludarabine-Clinical-BPCA.pdf
  31. https://www.fda.gov/drugs/development-resources/approved-active-moieties-have-appeared-national-institutes-healths-nih-annual-priority-list-which
  32. Pediatric Exclusivity Determinations List. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/132652/download
  33. Administrative and Correspondence document. NDA 205582. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205582Orig1s000AdminCorres.pdf
  34. FDA written requests issued. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/drugs/development-resources/written-requests-issued
  35. RACE. Retrieved from https://www.congress.gov/bill/114th-congress/senate-bill/3239
  36. Barone A, Casey D, McKee A, Reaman G. Cancer Drugs approved for use in children: Impact of legislative initiatives and future opportunities. Pediatric Blood and Cancer. 2019: 66(8): e27809
  37. Ye J, Reaman G, De Claro RA, Sridhara R. A Bayesian approach in design and analysis of pediatric cancer clinical trials. Pharmaceutical Statistics. 2020: doi.org/10.1002/pst.2039